Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
3(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
22%
Ph not_applicable
7
78%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
N/ANon-phased studies
7(77.8%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(5)

Detailed Status

Completed5
Recruiting3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (22.2%)
N/A7 (77.8%)

Trials by Status

recruiting333%
completed556%
not_yet_recruiting111%

Recent Activity

3 active trials
Showing 5 of 9
completednot_applicable

Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients

NCT04988750
completednot_applicable

NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

NCT04999046
recruitingphase_1

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT06329570
recruitingphase_1

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707
completednot_applicable

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NCT04446416
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04988750Not Applicable

Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients

Completed
NCT04999046Not Applicable

NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

Completed
NCT06329570Phase 1

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Recruiting
NCT06388707Phase 1

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

Recruiting
NCT04446416Not Applicable

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Completed
NCT07274787Not Applicable

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

Not Yet Recruiting
NCT05947656Not Applicable

Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Recruiting
NCT03860298Not Applicable

Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy

Completed
NCT03626896Not Applicable

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Completed

All 9 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
9